Tear Cathepsin S as a Candidate Biomarker for Sjögren's Syndrome

  • Sarah F. Hamm‐Alvarez
    University of Southern California School of Pharmacy Los Angeles
  • Srikanth R. Janga
    University of Southern California School of Pharmacy Los Angeles
  • Maria C. Edman
    University of Southern California School of Pharmacy Los Angeles
  • Sara Madrigal
    University of Southern California School of Pharmacy Los Angeles
  • Mihir Shah
    University of Southern California School of Pharmacy Los Angeles
  • Starleen E. Frousiakis
    University of Southern California Keck School of Medicine Los Angeles
  • Kavita Renduchintala
    University of Southern California Keck School of Medicine Los Angeles
  • Jay Zhu
    University of Southern California Keck School of Medicine Los Angeles
  • Seth Bricel
    University of Southern California Keck School of Medicine Los Angeles
  • Kimberly Silka
    University of Southern California Keck School of Medicine Los Angeles
  • Dianne Bach
    University of Southern California Keck School of Medicine Los Angeles
  • Martin Heur
    University of Southern California Keck School of Medicine Los Angeles
  • Stratos Christianakis
    University of Southern California Keck School of Medicine Los Angeles
  • Daniel G. Arkfeld
    University of Southern California Keck School of Medicine Los Angeles
  • John Irvine
    University of Southern California Keck School of Medicine Los Angeles
  • Wendy J. Mack
    University of Southern California Keck School of Medicine Los Angeles
  • William Stohl
    University of Southern California Keck School of Medicine Los Angeles

書誌事項

公開日
2014-06-27
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1002/art.38633
公開者
Wiley

この論文をさがす

説明

<jats:sec><jats:title>Objective</jats:title><jats:p>The diagnosis of Sjögren's syndrome (SS) in routine practice is largely a clinical one and requires a high index of suspicion by the treating physician. This great dependence on clinical judgment frequently leads to delayed diagnosis or misdiagnosis. Tear protein profiles have been proposed as simple and reliable biomarkers for the diagnosis of SS. Given that cathepsin S activity is increased in the lacrimal glands and tears of NOD mice (a murine model of SS), the aim of this study was to explore the clinical utility of using tear cathepsin S (CTSS) activity as a biomarker for SS.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A method to measure CTSS activity in tears eluted from Schirmer's test strips was developed and validated. Schirmer's tests were performed and CTSS activity measurements were obtained in 278 female subjects, including 73 with SS, 79 with rheumatoid arthritis, 40 with systemic lupus erythematosus, 10 with blepharitis, 31 with nonspecific dry eye disease, and 12 with other autoimmune diseases, as well as 33 healthy control subjects.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The median tear CTSS activity in patients with SS was 4.1‐fold higher than that in patients with other autoimmune diseases, 2.1‐fold higher than that in patients with nonspecific dry eye disease, and 41.1‐fold higher than that in healthy control subjects. Tear CTSS levels were equally elevated in patients with primary SS and those with secondary SS, independent of the Schirmer's test strip values or the levels of circulating anti‐SSA or anti‐SSB antibodies.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Markedly high levels of tear CTSS activity are suggestive of SS. CTSS activity in tears can be measured in a simple, quick, economical, and noninvasive manner and may serve as a novel biomarker for autoimmune dacryoadenitis during the diagnostic evaluation for SS.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ